Search
 

Pfizer to Shutter Princeton R&D Facility

PRINCETON, NJ-Pfizer Inc. announced this morning that it plans to close its Princeton, NJ R&D campus.

By Maria Wood | Updated on November 09, 2009

PRINCETON, NJ-Following its acquisition of Wyeth, Pfizer Inc. announced this morning that it plans to close its Princeton, NJ R&D campus. According to a company release, the company will consolidate to five main research sites in Cambridge, MA; Groton, CT; Pearl River, NY; La Jolla, CA; and Sandwich, UK and three research-oriented labs in San Francisco, Cambridge, UK and Shanghai, China.

“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” says Mikael Dolsten, president of BioTherapeutics Research & Development, in a statement. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”

As part of the consolidation, Pfizer will move a number of functions from Collegeville, PA.; Pearl River, NY; and St. Louis to other locations and will discontinue R&D operations in Princeton; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK. In addition, Pfizer will consolidate R&D functions from its New London, CT site to its nearby research facility in Groton.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2024 ALM Global, LLC. All Rights Reserved.